Circulation. 2009;119:3244-3262
Published online before print June 8, 2009,
doi: 10.1161/CIRCULATIONAHA.109.192521
(Circulation. 2009;119:3244-3262.)
© 2009 American Heart Association, Inc.
Exercise Training for Type 2 Diabetes Mellitus
Impact on Cardiovascular Risk: A Scientific Statement From the American Heart Association
Thomas H. Marwick, MD, PhD, Chair;
Matthew D. Hordern, PhD;
Todd Miller, MD, FAHA;
Deborah A. Chyun, RN, PhD, FAHA;
Alain G. Bertoni, MD, MPH, FAHA;
Roger S. Blumenthal, MD, FAHA;
George Philippides, MD;
Albert Rocchini, MD, FAHA, on behalf of the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Nutrition, Physical Activity, and Metabolism; and the Interdisciplinary Council on Quality of Care and Outcomes Research
Key Words: AHA Scientific Statements exercise diabetes mellitus prevention risk factors
An extract of the first 250 words of the full text is provided, because this article has no abstract.
|
 |
Introduction
|
|---|
- Introduction ...3244
- Beneficial Effects of Exercise in T2DM...3245
- Glycemic Control...3245
- Body Composition...3248
- Risk Factors...3248
- Vascular Effects...3248
- Myocardial Function...3248
- Development of CVD...3248
- Cardiac Risks of Exercise Training in T2DM...3249
- Generic Cardiac Risks of Training...3249
- Screening for Coronary Artery Disease...3249
- Prior Studies of CAD Screening...3249
- Guidelines/Position Statements...3250
- Noncardiac Risks of Exercise Training in T2DM...3251
- Hypoglycemia...3251
- Peripheral Arterial Disease and Foot Care...3251
- Microvascular Disease...3252
- Exercise Training Guidelines...3252
- Preparation for Exercise...3253
- Frequency...3253
- Intensity...3253
- Duration...3254
- Session Duration...3254
- Program Duration...3254
- Type...3254
- Aerobic...3254
- Resistance...3254
- Approaches to Adherence...3254
- Health Behavior...3254
- Counseling...3255
- Long-Term Efficacy...3255
- Special/Minority Groups...3255
- Conclusions...3256
- References...3257
 |
1. Introduction
|
|---|
The increasing prevalence of overweight and obesity has led
to an unprecedented epidemic of type 2 diabetes mellitus (T2DM)
1–4 and is likely to be followed by an epidemic of patients with
complications of T2DM.
5 Given the observed increases in the
prevalence of T2DM in adults over the past few decades in developed
countries,
1,2,6 population-based efforts to reduce the cardiovascular
complications of T2DM are as critical as the measures to prevent
the problem.
4,7 T2DM is the sixth-leading cause of death,
8 with
most deaths attributed to cardiovascular disease (CVD; nearly
70%) and with ischemic heart disease being responsible for nearly
50% of these deaths.
9 The economic cost of T2DM has been estimated
to be $172 billion in 2007 in the United States alone
3 (up from
$132 billion in 2002)
10 and is likely to be greater when the
other indirect costs of its associated complications are included.
11 These complications are due to atherosclerotic vascular disease
4 but also reflect a susceptibility of patients with T2DM
. . . [Full Text of this Article]
Related Internet Resources:
- Supporting Materials From the American Heart Association
This article has been cited by other articles:

|
 |

|
 |
 
S. Stern and S. Sclarowsky
The ECG in Diabetes Mellitus
Circulation,
October 20, 2009;
120(16):
1633 - 1636.
[Full Text]
[PDF]
|
 |
|